Friday, January 11, 2013
Stemline Therapeutics Inc., of New York, again revised the terms for its proposed initial public offering (IPO), increasing the number of shares from 1.8 million to 2.3 million, priced between $10 and $12. At the midpoint range, the offering would bring in $25.3 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.